Reuters
29 Sept 2026, 00:18 UTC · 1h ago
Verdict
Headline takes no side. We score AZN +0.60 across one claim — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
AstraZeneca has filed a US FDA application for the ORPATHYS-TAGRISSO combination for advanced lung cancer patients.
NewHUTCHMED said on Tuesday
So whatFDA approval typically takes 6-10 months, shifting potential US revenue realization to 2027.
More positive than 93% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
9h ago
—
AZN hasn't traded since this ran. Last close $166.15 (Sep 28); the reaction starts at the next open.
AZN chart →
